InDex Pharmaceuticals Holding AB (publ) year end report 2018
Continued focus on the patient recruitment for the CONDUCT studyPeriod October – December 2018 · Revenues amounted to SEK 0.6 (0.0) million · Operating result amounted to SEK –22.5 (–22.6) million · Result after tax amounted to SEK –22.5 (–22.4) million, corresponding to SEK –0.33 per share (–0.36) before and after dilution · Cash flow from operating activities amounted to SEK –20.9 (–14.1) million Period January – December 2018 · Revenues amounted to SEK 0.7 (0.1) million · Operating result amounted to SEK –82.4 (–73.3) million · Result after tax